drugset / Trial / NCT04674813
A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).
Timeline
- Start
- 2021-02-24
- Primary completion
- 2025-12-22
- Completion
- 2025-12-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arlocabtagene Autoleucel | Unknown | — | — |
| Background | Bendamustine | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | Fludarabine | Small molecule | — | — |